Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90B1 | P14625 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.55 |
| ▸ | HINT1 | P49773 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047557 | 0.88 | NT5E (0.65) | ADORA3ADORA2BADORA2ANT5EADORA1 | |
| SCHEMBL800659 | 0.88 | NT5E (0.55) | HSP90B1ADORA3ADORA2BADORA2ANT5E | |
| SCHEMBL3053788 | 0.88 | NT5E (0.65) | ADORA3ADORA2BADORA2ANT5EADORA1 | |
| SCHEMBL6829145 | 0.87 | HINT1 (0.56) | HSP90B1ADORA3HINT1ADORA2BADORA2A | |
| SCHEMBL800346 | 0.84 | PRMT5 (0.64) | HSP90B1ADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL22326787 | 0.84 | PRMT5 (0.64) | HSP90B1ADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL22326785 | 0.84 | PRMT5 (0.64) | HSP90B1ADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL21413837 | 0.84 | PRMT5 (0.64) | HSP90B1ADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL18520788 | 0.84 | PRMT5 (0.64) | HSP90B1ADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL13173634 | 0.84 | PRMT5 (0.64) | HSP90B1ADORA3ADORA2BADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | HSP90B1 1907/4885ADORA3 174/4885HINT1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.